Wegovy vs Saxenda: semaglutido semanal versus liraglutido diário.

Section 01

Quick answer

For most patients beginning treatment in 2026, Wegovy is the more effective and more convenient choice. Saxenda still has a role — particularly in step therapy protocols, in patients who tolerated it well in the past, and in situations where rapid medication washout is desirable. The rest of this guide explains those distinctions in detail.

Section 02

Comparison table

The numbers below come from the FDA prescribing information for each drug and from the manufacturer's pivotal trials. List prices are average U.S. retail figures as of April 2026 and are subject to change.

A few things stand out at a glance. Same drug class, same manufacturer, same general indication — but very different dose schedules, very different weight loss outcomes, and a seven-year gap in FDA approval. Saxenda was the first drug in this class approved for weight loss; Wegovy was built on what Novo Nordisk learned from it.

Section 03

Same class, different molecules: semaglutide vs liraglutide

Both semaglutide and liraglutide are GLP-1 receptor agonists — synthetic peptides engineered to mimic the natural gut hormone glucagon-like peptide-1. Natural GLP-1 is released by the small intestine after a meal. It signals fullness to the brain, slows stomach emptying, and stimulates insulin release. The body breaks it down within minutes, which is why a synthetic version is needed for therapeutic use.

Liraglutide was the first long-acting GLP-1 designed for once-daily use. Novo Nordisk modified the natural human GLP-1 sequence by adding a fatty acid side chain that lets it bind reversibly to albumin in the blood. That modification stretched the half-life from about two minutes to roughly 13 hours — long enough for once-a-day dosing.

Semaglutide is the next generation. It uses a similar fatty acid trick but with additional amino acid substitutions that further protect the molecule from enzymatic breakdown. The result is a half-life of about 165 hours, or roughly seven days. That single biochemical improvement is why one drug is taken weekly and the other daily — and it has knock-on effects on patient adherence, plasma drug levels, and overall weight loss.

Receptor binding and selectivity

Both drugs activate the GLP-1 receptor with high specificity. Neither one targets the GIP receptor, which is what sets them apart from tirzepatide (the active ingredient in Zepbound and Mounjaro). At the receptor level, semaglutide and liraglutide work very similarly. The differences in clinical outcomes come from drug exposure and the higher steady-state concentrations Wegovy can sustain.

Section 04

Weekly vs daily injection — the practical difference

On paper, the difference between one injection per week and one per day looks small. In real life it shapes how patients experience the drug, how easy it is to stay on it for years, and whether weight loss actually translates into long-term success.

The adherence gap is the real headline. A 2023 retrospective study of commercial pharmacy claims found that approximately 65% of patients on a weekly GLP-1 were still filling prescriptions at 12 months, compared to only about 30% of patients on a daily GLP-1. Weight loss medications only work while you take them, so adherence is not a trivial concern — it directly translates into outcomes.

Daily injection is also a quiet psychological burden. Many patients describe Saxenda as "another thing on the list" along with brushing teeth and taking morning supplements. Wegovy's once-a-week routine is easier to anchor to a recurring event — Sunday morning coffee, for example — and fades into the background of normal life.

Section 05

Effectiveness: Wegovy wins on weight loss

Both drugs were tested in large randomized trials against placebo. They were also tested against each other directly. The data tells a clear story.

The STEP 8 trial is the most important result here because it compared the two drugs head-to-head in the same population over the same duration. Adults on semaglutide lost 15.8% of body weight at 68 weeks; adults on liraglutide lost 6.4%. That is more than double. STEP 8 also looked at the proportion of patients hitting weight-loss milestones: 70% of the semaglutide group lost at least 10% of body weight, compared to 26% of the liraglutide group.

Why such a big gap when the drugs work on the same receptor? Two reasons. First, semaglutide can be dosed to higher cumulative weekly exposure — 2.4 mg once a week versus 3.0 mg per day, or 21 mg per week. Second, the smoother weekly pharmacokinetics produce more sustained appetite suppression than the daily peak-and-trough pattern of liraglutide. Both factors combine to drive the difference.

For patients still considering options, our Wegovy vs Zepbound comparison covers the third drug in this conversation — tirzepatide produces about 20.9% weight loss in trials, more than either GLP-1 alone.

Section 06

Side effect profile

Because Wegovy and Saxenda activate the same GLP-1 receptor, their side effect profiles are almost identical. The most common adverse events are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. The frequency, severity, and onset are broadly similar between the two drugs in clinical trials.

Wegovy's higher rates partly reflect the higher cumulative drug exposure — patients are on a stronger dose for longer. Despite that, fewer people quit Wegovy due to side effects than quit Saxenda, suggesting the smoother weekly pharmacokinetics may be slightly easier to live with day to day.

Both drugs share the same serious-but-rare warnings: pancreatitis, gallbladder disease, kidney injury from dehydration, and a boxed warning about thyroid C-cell tumors observed in rodent studies. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Our Wegovy side effects guide covers these in more depth and applies to Saxenda almost word for word.

Section 07

Cost and insurance

Sticker prices for Wegovy and Saxenda are nearly identical. Both list at roughly $1,349 per month at most U.S. retail pharmacies. The differences show up in the discount programs and how each manufacturer routes uninsured patients.

For uninsured patients in 2026, Wegovy is meaningfully cheaper than Saxenda because of the NovoCare $499 self-pay option. Saxenda has not introduced an equivalent program, so an uninsured patient on Saxenda is generally paying full retail or hunting for GoodRx coupons that bring it to roughly $1,200 per month.

For insured patients, the picture flips. Many commercial formularies still cover Saxenda more reliably than Wegovy, and the Saxenda Savings Card brings the copay down to $25 for eligible patients. We break down all of this in the Wegovy cost guide.

Section 08

Step therapy: when your insurance makes you try Saxenda first

Step therapy — also called "fail first" — is a cost-control policy used by pharmacy benefit managers and health insurers. It requires patients to try a less expensive or older drug before the insurer will pay for a newer or pricier alternative. For GLP-1 weight loss drugs, that often means trying Saxenda before getting Wegovy approved.

The logic from the insurer's side is straightforward. Both drugs are expensive. Saxenda has been on formularies longer, has been negotiated to lower net prices in some plans, and demonstrably produces clinical weight loss for many patients. Insurers reason that if a patient does well on Saxenda, the plan saves money. If the patient fails or cannot tolerate Saxenda, the request for Wegovy can then be approved on appeal.

How a typical step therapy protocol looks

1. Your provider prescribes Wegovy at your first visit.
2. The pharmacy submits the claim. Insurance rejects it citing step therapy.
3. Your provider receives a denial letter explaining the requirement: typically a 12 to 16 week trial of Saxenda at the maximum tolerated dose.
4. You start Saxenda. If you lose weight and tolerate it, the plan generally expects you to stay on Saxenda.
5. If you do not lose at least 5% of your starting weight by week 12 to 16, or if you cannot tolerate the drug due to side effects, your provider can submit a step therapy override or prior authorization for Wegovy.
6. Wegovy is then approved (often with a separate prior authorization for medical necessity).

Patience helps. So does documentation. Keep a written log of side effects, dose changes, and your weight measurements. If you need to escalate a denial, that paper trail is what your provider will use to argue medical necessity.

Section 09

Who Saxenda might still be right for

Wegovy is more effective for most patients, but Saxenda is not obsolete. There are several scenarios where it remains a reasonable or even preferred choice.

• Step therapy patients. If your insurance plan requires a Saxenda trial before approving Wegovy, the easiest path is to take Saxenda properly for the required period and then transition. Fighting the protocol can delay treatment by months.
• Patients who tolerated it well in the past. Some people came off Saxenda for non-medical reasons — cost, life events, discontinuation by a previous provider — and want to restart something familiar. Restarting a drug you already know how to use is often easier than learning a new one.
• Patients who want fast washout. Liraglutide leaves the body within a few days. Semaglutide takes weeks to clear. If you have a planned surgery, a pregnancy plan, or a known sensitivity to GLP-1 effects, the shorter half-life of Saxenda gives more control.
• Pediatric patients aged 12-17. Saxenda was FDA-approved for adolescents with obesity in 2020, and Wegovy received pediatric approval in 2022. Both are now options, but some pediatric obesity specialists still default to Saxenda because they have more years of clinical experience with it in younger patients.
• People who genuinely prefer daily routines. A small group of patients prefers daily dosing because it feels more like "taking control" or fits better with their habit-tracking system. For these patients, the daily injection is a feature, not a bug.

Saxenda was a breakthrough in 2014. It was the first injectable GLP-1 specifically indicated for chronic weight management and it built the clinical foundation for everything that came after. It is reasonable to use it; it is just no longer the most effective option for most new patients.

Section 10

Can you switch from Saxenda to Wegovy

Yes, and the transition is one of the simpler medication changes in this category because both drugs are made by the same manufacturer and act on the same receptor. There is no required washout period between them.

Typical switching protocol

1. Take your last dose of Saxenda on a chosen "switch day."
2. Wait one full day to clear most of the liraglutide from your system.
3. Start Wegovy at the standard 0.25 mg weekly starting dose, even if you were on the maximum 3.0 mg of Saxenda.
4. Follow the standard 16 to 20 week titration up to 2.4 mg weekly.

The reason providers do not skip the Wegovy titration is tolerability. Even though your body is used to liraglutide, semaglutide has different pharmacokinetics and a higher cumulative weekly dose. Starting at 0.25 mg minimizes the risk of nausea and vomiting in the first few weeks. Most patients who switch report either similar or fewer GI side effects than they had on Saxenda, partly because they are no longer experiencing daily peak doses.

Insurance approvals for the switch usually require documentation of either inadequate weight loss on Saxenda (less than 5% at 12-16 weeks) or intolerable side effects. Some plans approve the switch automatically after a documented Saxenda trial; others require a fresh prior authorization. Our cost and insurance guide has more on the prior authorization process.

Section 11

Briefly: how does Contrave fit in?

Contrave (bupropion plus naltrexone) is a third option that comes up in the same conversation. It is worth a short mention because some patients are weighing all three drugs simultaneously.

Contrave is an oral pill, not an injection, and it is not a GLP-1. It combines an antidepressant (bupropion) with an opioid antagonist (naltrexone) to reduce appetite and food cravings through brain reward pathways. In its pivotal trials, average weight loss was approximately 5% of body weight at one year — meaningfully less than Saxenda's 8% and far less than Wegovy's 14.9%.

Contrave has its own side effect profile: nausea, headache, constipation, dizziness, insomnia, and dry mouth. It is contraindicated in patients with seizure disorders, eating disorders, uncontrolled hypertension, or chronic opioid use. List price runs roughly $700 per month, with manufacturer savings cards bringing it as low as $99 per month for eligible patients.

For patients who refuse injections or who have a specific contraindication to GLP-1 drugs, Contrave is a real option. For most others, even Saxenda outperforms it. Wegovy remains the more effective choice for nearly anyone who can tolerate injections.

Section 12

The bottom line

Wegovy and Saxenda are siblings. Same drug class, same manufacturer, same general indication. The differences are real and meaningful: Wegovy delivers roughly twice the weight loss of Saxenda, in one weekly injection instead of seven, with comparable side effects and a cheaper self-pay path. That is why most new patients in 2026 start on Wegovy.

Saxenda still matters. It opened the door for an entire category of weight loss medication and remains a practical choice for step therapy compliance, restart patients, and short-half-life situations. It is not an inferior drug — it is an older drug that has been outperformed by its own next generation.

If you are weighing your options, the most useful next steps are to check your insurance formulary, look up the current pricing in detail, and consider ordering online from our partner pharmacy, where coupon WEGOVY2026 takes 10% off the cash price.

You may also want to read our other comparison guides: Wegovy vs Ozempic, Wegovy vs Zepbound, or the full comparison table of all GLP-1 weight loss drugs.

Frequently Asked Questions

O Wegovy é melhor do que o Saxenda para a perda de peso?

Em média, sim. No ensaio STEP 1, os adultos a tomar Wegovy 2.4 mg perderam cerca de 14.9% do peso corporal às 68 semanas. No ensaio SCALE Obesity and Prediabetes, os adultos a tomar Saxenda 3.0 mg perderam cerca de 8% às 56 semanas. Um ensaio direto chamado STEP 8 comparou os dois medicamentos diretamente e concluiu que o semaglutido produziu aproximadamente o dobro da perda de peso do liraglutido no mesmo momento.

Porque tenho de injetar o Saxenda todos os dias mas o Wegovy apenas uma vez por semana?

O liraglutido, o princípio ativo do Saxenda, tem uma semivida de cerca de 13 horas. O semaglutido, o princípio ativo do Wegovy, tem uma semivida de cerca de uma semana — aproximadamente 165 horas. A Novo Nordisk concebeu o semaglutido com uma cadeia de ácido gordo que lhe permite ligar-se à albumina no sangue, abrandando drasticamente a sua degradação. Essa diferença estrutural é a única razão pela qual um medicamento é diário e o outro semanal.

Posso mudar do Saxenda para o Wegovy?

Sim, e muitos doentes fazem-no. A transição é geralmente simples porque ambos os medicamentos são agonistas do recetor GLP-1 fabricados pelo mesmo laboratório. A maioria dos médicos suspende o Saxenda e inicia o Wegovy na sua dose inicial padrão de 0.25 mg, aumentando depois a dose ao longo de 16 a 20 semanas. A sua tolerância prévia ao liraglutido é uma pista útil, mas não lhe permite saltar o esquema de titulação do Wegovy.

O seguro cobre o Saxenda ou o Wegovy mais facilmente?

O Saxenda está no mercado desde 2014 e por vezes consta de formulários que ainda não incluem o Wegovy. Muitos planos comerciais usam terapia escalonada, que exige que os doentes experimentem primeiro o Saxenda e que falhem ou deixem de o tolerar antes de aprovarem o Wegovy. A cobertura varia enormemente consoante o plano, o empregador e o gestor de benefícios farmacêuticos, pelo que verificar o seu formulário específico é a única forma de saber.

Os efeitos secundários do Wegovy e do Saxenda são iguais?

São muito semelhantes porque ambos os medicamentos ativam o mesmo recetor GLP-1. As náuseas, a diarreia, os vómitos, a obstipação e a dor abdominal são os efeitos secundários mais comuns de ambos. Alguns doentes toleram um medicamento melhor do que o outro, mas não há evidência consistente de que algum deles tenha um perfil gastrointestinal significativamente mais suave. Ambos têm a mesma advertência em caixa sobre tumores das células C da tiroide observados em estudos com roedores.

Quanto custa o Saxenda em comparação com o Wegovy?

O preço de tabela de venda ao público do Saxenda ronda os $1,349 por mês, quase idêntico ao do Wegovy. Com seguro comercial e o Saxenda Savings Card, os doentes elegíveis podem pagar apenas $25 por mês durante um máximo de 24 meses. Os doentes de Wegovy podem usar a opção de pagamento direto da NovoCare a $499 por mês, algo que o Saxenda atualmente não iguala. Para os doentes sem seguro, o Wegovy costuma ser mais barato do próprio bolso.

O Saxenda vai ser descontinuado?

Não, o Saxenda não foi descontinuado. A Novo Nordisk continua a fabricá-lo e a distribuí-lo nos Estados Unidos. No entanto, a prescrição deslocou-se fortemente para o Wegovy e o Zepbound desde 2021, e algumas farmácias têm menos stock do que costumavam. Se a sua farmácia estiver com pouco Saxenda, pergunte se outra farmácia local o tem ou se o seu médico pode encaminhar a receita médica para a NovoCare.

O Saxenda é o mesmo que o Victoza?

Ambos contêm liraglutido e são fabricados pela Novo Nordisk, mas não são o mesmo medicamento e não são intermutáveis. O Victoza é aprovado para a diabetes tipo 2 em doses até 1.8 mg por dia. O Saxenda é aprovado para a gestão do peso crónica em doses até 3.0 mg por dia. A dose máxima para a perda de peso é superior à dose máxima para a diabetes, razão pela qual são vendidos como produtos separados.

Como se compara o Contrave com o Wegovy?

O Contrave é um comprimido oral que combina bupropiom e naltrexona. Não é um GLP-1 e atua antes nas vias de recompensa e apetite do cérebro. A perda de peso média com o Contrave ronda os 5% do peso corporal ao fim de um ano, em comparação com 14.9% do Wegovy. O Contrave é mais barato e em comprimido, mas nitidamente menos eficaz. É por vezes preferido por doentes que não podem ou não querem injetar-se.

Qual é melhor para alguém com mais de 65 anos?

Ambos os medicamentos são estudados e usados em adultos mais velhos, mas nenhum é aprovado pela FDA especificamente para a população geriátrica. Os adultos mais velhos que tomam vários medicamentos e com risco de desidratação, problemas renais ou sarcopenia devem ser monitorizados com cuidado. Alguns clínicos preferem começar com o Saxenda porque a dose diária facilita a paragem rápida caso surja um problema, enquanto outros preferem o Wegovy pelo seu perfil semanal mais suave e pela base de evidência mais sólida.